8-K: Halozyme Raises 2025 Guidance on Strong Q2 Growth

Halozyme Therapeutics reported strong second quarter 2025 financial results, driven by significant royalty revenue growth, and subsequently raised its full-year 2025 financial guidance ranges.

Summary

• Total Revenue for Q2 2025 increased 41% year-over-year to $325.7 million, compared to $231.4 million in Q2 2024.
• Royalty Revenue for Q2 2025 increased 65% year-over-year to $205.6 million, primarily driven by DARZALEX SC, Phesgo, and VYVGART Hytrulo.
• Net Income for Q2 2025 increased 77% year-over-year to $165.2 million, compared to $93.2 million in Q2 2024.
• Adjusted EBITDA for Q2 2025 increased 65% year-over-year to $225.5 million, compared to $137.0 million in Q2 2024.
• GAAP Diluted EPS for Q2 2025 increased 85% year-over-year to $1.33, compared to $0.72 in Q2 2024.
• Non-GAAP Diluted EPS for Q2 2025 increased 69% year-over-year to $1.54, compared to $0.91 in Q2 2024.
• The company raised its full-year 2025 Total Revenue guidance to a range of $1,275 million to $1,355 million, representing 26% to 33% year-over-year growth.
• The company raised its full-year 2025 Adjusted EBITDA guidance to a range of $865 million to $915 million, representing 37% to 45% year-over-year growth.
• The company raised its full-year 2025 Non-GAAP Diluted EPS guidance to a range of $6.00 to $6.40, representing 42% to 51% year-over-year growth.
• Halozyme initiated the third $250 million share repurchase tranche under its $750 million authorized program in June 2025, having completed $303.4 million in share repurchases in Q2 2025.

Sentiment

Score: 9

Explanation: The company reported exceptional financial growth across all key metrics, significantly exceeding prior year results. It also raised its full-year financial guidance for the second time, indicating strong confidence in continued performance. Multiple regulatory approvals for its core technology-enabled products further de-risk future revenue streams. The only minor negative is a decrease in cash due to share repurchases, which is a planned capital allocation strategy, and ongoing litigation costs, which are manageable given the strong financial performance.

Positives

• Significant year-over-year growth across all key financial metrics: Total Revenue increased 41%, Royalty Revenue increased 65%, Net Income increased 77%, Adjusted EBITDA increased 65%, GAAP Diluted EPS increased 85%, and Non-GAAP Diluted EPS increased 69%.
• Strong royalty revenue growth driven by three blockbuster therapies: DARZALEX SC, Phesgo, and VYVGART Hytrulo.
• Multiple notable regulatory approvals for ENHANZE-enabled products, including RYBREVANT SC in Europe, VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Europe, and the VYVGART Hytrulo pre-filled syringe for gMG and CIDP in the U.S. and Europe.
• Additional ENHANZE regulatory milestones achieved, including new indications and geographic expansion for DARZALEX SC, Opdivo SC, HYQVIA, and Phesgo.
• Full-year 2025 financial guidance ranges for Total Revenue, Adjusted EBITDA, and Non-GAAP Diluted EPS were raised for the second time this year, indicating strong confidence in continued performance.
• Completed $303 million in share repurchases in Q2 2025, including the completion of a $250 million program announced in May, demonstrating a commitment to returning capital to shareholders.
• ENHANZE drug delivery technology has touched one million patient lives in post-marketing use across ten commercialized products in at least one major region and over 100 global markets.

Negatives

• Cash, cash equivalents, and marketable securities decreased to $548.2 million on June 30, 2025, from $596.1 million on December 31, 2024, primarily due to share repurchase activities.
• Selling, general and administrative expense increased to $41.6 million in Q2 2025 from $35.7 million in Q2 2024, partly due to $2.6 million in litigation costs incurred in connection with a patent infringement case.

Risks

• Halozyme filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. in April 2025, alleging the use of Halozyme's patented MDASE subcutaneous (SC) drug delivery technology for SC Keytruda, seeking damages and injunctive relief.
• There is no assurance as to developments related to the patent litigation, its outcome, or any remedies that could be awarded.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, including unexpected levels of revenues, expenditures and costs, unexpected delays in the execution of the share repurchase program or planned platform expansion through acquisitions.
• Uncertainties related to tariffs, trade, and pharmaceutical pricing policies and tax legislation could impact financial performance.
• Unexpected adverse events or patient outcomes and competitive conditions could affect the company's business.

Future Outlook

Halozyme Therapeutics is raising its full-year 2025 financial guidance for the second time this year, expecting total revenue between $1,275 million and $1,355 million, royalty revenue between $825 million and $860 million, adjusted EBITDA between $865 million and $915 million, and non-GAAP diluted EPS between $6.00 and $6.40. This guidance reflects anticipated continued strong growth, primarily driven by increasing royalty revenue from its ENHANZE technology, and does not consider the impact of potential future share repurchases.

Management Comments

• "We are very excited to report another quarter of exceptional growth with a 65% increase in royalty revenue driven by our current three blockbuster therapies, DARZALEX SC, Phesgo, and VYVGART Hytrulo." Dr. Helen Torley, President and CEO, Halozyme.
• "Based on the strong performance and growth trends, we are pleased to increase our full-year 2025 financial guidance ranges for the second time this year." Dr. Helen Torley, President and CEO, Halozyme.
• "The strong results highlight the momentum and durability across our business, powered by high-margin royalty streams and increasing global demand for our industry-leading ENHANZE drug delivery technology." Dr. Helen Torley, President and CEO, Halozyme.
• "Our outperformance and strong cash generation supports a balanced capital allocation strategy, including investing in growth through M&A and returning capital to shareholders." Dr. Helen Torley, President and CEO, Halozyme.

Industry Context

Halozyme's strong performance, driven by its ENHANZE drug delivery technology, underscores a growing industry trend towards subcutaneous drug administration. This technology improves patient experience by enabling rapid delivery and administration of higher volumes of injectable medications, aligning with broader healthcare goals of enhancing patient convenience and adherence. The multiple regulatory approvals for ENHANZE-enabled products across various therapeutic areas (oncology, neurology, immunology) demonstrate the versatility and increasing adoption of this platform by leading pharmaceutical companies, positioning Halozyme as a key enabler in the biopharmaceutical landscape. The patent litigation against Merck highlights the increasing value and competitive landscape surrounding innovative drug delivery technologies.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to industry standards.
• Halozyme's ENHANZE technology is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, and Acumen Pharmaceuticals, indicating its broad acceptance and utility within the industry.
• The commercialization of ten partnered products with ENHANZE, having touched one million patient lives in post-marketing use across more than 100 global markets, suggests a significant market penetration and validation of its technology compared to other drug delivery platforms.

Legal Proceedings

• Halozyme filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. in the U.S. District Court in New Jersey in April 2025.
• The lawsuit alleges Merck is using Halozyme's patented MDASE subcutaneous (SC) drug delivery technology to develop SC Keytruda.
• Halozyme is seeking damages and injunctive relief to stop Merck's infringement of its MDASE intellectual property.
• The company incurred $2.6 million in litigation costs in Q2 2025 related to this case.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased guidance, and ongoing share repurchase program ($303 million in Q2 2025, third $250 million tranche initiated), indicating strong capital returns.
• Patients: Positive impact through increased access to subcutaneous drug delivery via ENHANZE technology, leading to reduced treatment burden and improved convenience for therapies like DARZALEX SC, Phesgo, VYVGART Hytrulo, RYBREVANT SC, Opdivo SC, and HYQVIA.
• Partners: Continued successful collaborations and regulatory approvals for ENHANZE-enabled products, leading to milestone payments and increased royalty streams for Halozyme.
• Employees: Resource optimization and labor allocation initiatives mentioned, leading to lower R&D compensation expense, but overall compensation expense increased in SG&A.

Next Steps

• Continued development and commercialization efforts by partners for ENHANZE-enabled products.
• Potential new clinical trial study starts and clinical data for partnered products.
• Regulatory submissions and product launches for partnered or proprietary products.
• Potential new or expanded collaborations, including potential HVAI and SVAI collaborations.
• Ongoing patent infringement litigation against Merck Sharp & Dohme Corp.
• Potential future share repurchases under the authorized program.
• Potential expansion of the company's platform through acquisitions.

Key Dates

Recommendation

Halozyme's Q2 2025 results significantly exceeded expectations, demonstrating robust growth across all key financial metrics, particularly high-margin royalty revenue. The company's decision to raise its full-year 2025 guidance for the second time this year signals strong underlying business momentum and management confidence. The ENHANZE technology continues to gain widespread adoption with multiple new regulatory approvals and expanded indications for blockbuster therapies, solidifying its market position. While litigation costs and a decrease in cash due to share repurchases are noted, the latter is a strategic capital return, and the former is a manageable expense given the company's profitability. The strong financial performance, coupled with a clear growth trajectory and shareholder-friendly capital allocation, makes Halozyme a compelling investment.

Keywords

Halozyme, HALO, biopharmaceutical, ENHANZE, drug delivery, rHuPH20, subcutaneous, DARZALEX SC, Phesgo, VYVGART Hytrulo, RYBREVANT SC, Opdivo SC, HYQVIA, Keytruda, patent infringement, Q2 2025 earnings, financial guidance, share repurchase, biotech, pharmaceuticals, oncology, neurology, immunology